April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal Sirolimus for the Treatment of Bilateral Geographic Atrophy Associated with Age-Related Macular Degeneration: Results of a Phase I/II Trial
Author Affiliations & Notes
  • Philip A Petrou
    Unit on Neuron-Glia Interactions in Retinal Disease, National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Katherine Shimel
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Catherine A Cukras
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Frederick L Ferris
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Emily Y Chew
    National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Wai T Wong
    Unit on Neuron-Glia Interactions in Retinal Disease, National Eye Institute, National Institutes of Health (NIH), Bethesda, MD
  • Footnotes
    Commercial Relationships Philip Petrou, None; Katherine Shimel, None; Catherine Cukras, None; Frederick Ferris, None; Emily Chew, None; Wai Wong, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5892. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Philip A Petrou, Katherine Shimel, Catherine A Cukras, Frederick L Ferris, Emily Y Chew, Wai T Wong; Intravitreal Sirolimus for the Treatment of Bilateral Geographic Atrophy Associated with Age-Related Macular Degeneration: Results of a Phase I/II Trial. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5892.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To investigate the safety and effects of intravitreal sirolimus, an mTOR inhibitor and immunosuppressive agent, for the treatment of bilateral geographic atrophy (GA).

 
Methods
 

The study was a single-center, open-label phase I/II trial, with intravitreal injections of sirolimus (440 µg) every 2 months in a randomly assigned eye of each participant for 24 months. Fellow eyes served as untreated controls. Safety and tolerability were evaluated, and efficacy outcome measures included: change in the total GA area as measured by color fundus photography (CFP) and autofluorescence (AF) imaging, visual acuity, central retinal thickness (CRT), and macular sensitivity. Paired t-tests were used to compare measures in treated vs. control eyes.

 
Results
 

The study enrolled 6 participants with bilateral GA; 5 participants completed 12 months of follow-up. During the study, drug administration was suspended for all participants after 2-3 doses following the detection of retinal changes in 2/6 participants that were judged inconsistent with the natural progression of GA. These included: 1) accelerated retinal thinning in the study eye in 2 participants, and 2) accelerated GA area expansion in 1 participant. Comparisons of study vs. fellow eyes respectively showed that mean GA area growth on CFP was 2.1 ± 1.4 vs. 0.9 ± 0.5 mm2 at month 6 (n = 5, p = 0.13) and 2.3 ± 0.9 vs. 1.5 ± 0.7 mm2 at month 12 (n = 5, p = 0.15). Similar results were obtained with AF imaging. Mean change in CRT was -27.4 ± 20.1 vs. +1.0 ± 6.6 µm at month 6 (n = 5, p = 0.04) and -23.8 ± 27.7 vs. -13.8 ± 8.5 µm at month 12 (n = 5, p = 0.32). Mean visual acuity change was -15.6 ± 7.2 vs. 0.0 ± 13.5 letters at month 12 (n = 5, p = 0.013). Substantive differences in macular perimetry measurements were not detected between study and fellow eyes. Study drug was otherwise well-tolerated with few related systemic symptoms and adverse events.

 
Conclusions
 

No evidence of anatomical or functional benefit was associated with study drug in this small study. In general, intravitreal sirolimus appeared safe, but may potentially be associated with an increase in retinal thinning and GA expansion in a subset of patients. Further data on the effects of intravitreal sirolimus for GA treatment will be available from a larger ongoing phase II trial.

 
Keywords: 412 age-related macular degeneration • 555 immunomodulation/immunoregulation • 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×